Severity: Warning

Message: fopen(/home/oaponnap/tmp/ci_sessionc15542cb13770c7a2124d13367746899): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 157

Backtrace:

File: /home/oaponnap/public_html/innovationinfo.org/application/controllers/Journalnew.php
Line: 8
Function: __construct

File: /home/oaponnap/public_html/innovationinfo.org/index.php
Line: 315
Function: require_once

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /home/oaponnap/tmp)

Filename: Session/Session.php

Line Number: 141

Backtrace:

File: /home/oaponnap/public_html/innovationinfo.org/application/controllers/Journalnew.php
Line: 8
Function: __construct

File: /home/oaponnap/public_html/innovationinfo.org/index.php
Line: 315
Function: require_once

Journal of Clinical Case Reports and Trials

Manuscript for Review Process

One Year Follow up of 50 Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) after Pharmacological Treatment

Abstract:

Non-Alcoholic Fatty Liver Disease (NAFLD), is one of the most prevalent liver diseases

worldwide which is raised up increasingly in incidence and prevalence (1). It is defined by

liver accumulation of triglycerides and free fatty acids (2). Metabolic risk factors associated

with NAFLD are obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia (3). NAFLD

patients may develop progressive fibrosis which yields eventually to progressive steatosis with

associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma (HCC)

(4).

Keywords:

Non-Alcoholic Fatty Liver Disease, Metformin, Dyslipidemia.